Some flu measures decrease, but no clear sign this severe season has peaked

U.S. flu activity showed a slight decline in outpatient visits and the number of states reporting high activity, but hospitalizations and deaths rose, and experts caution the season has not peaked. The A H3N2 strain predominates, with over 91% of analyzed H3N2 infections identified as the K subclade that differs from this season's vaccine; the CDC estimates at least 15 million illnesses, 180,000 hospitalizations and 7,400 deaths (including at least 17 children) so far. Federal health officials recently announced they will no longer recommend routine flu vaccination for U.S. children, a policy shift drawing criticism from advocacy groups and adding uncertainty to pediatric protection strategies.

Analysis

Market structure: Acute rise in H3N2 (subclade K >91%) that mismatches this season's vaccine shifts near-term demand to diagnostics (testing volumes), hospital capacity and antivirals. Direct beneficiaries: DGX, LH (testing), HCA, UNH (hospital utilization & payer flows), SNY/GSK/PFE/MRNA (vaccine/antiviral makers); losers: travel/leisure (AAL, IYT), pediatric-focused elective care and vaccine distributors if uptake falls. Expect pricing power for outpatient testing + urgent care for 4–12 weeks; hospital beds and ICU mix will determine net margins for payers over Q1–Q2 2026.

Risk assessment: Tail risks include a prolonged season or a second wave (10–30% chance) driven by vaccine mismatch and holiday movement, and regulatory/legal fallout from the CDC’s child-vaccine guidance causing litigation or state-level mandates. Immediate horizon (days): spikes in testing; short (weeks–months): elevated hospital utilization and diagnostic revenues; long (quarters): potential margin pressure for insurers if sustained hospitalization >20% above baseline. Hidden dependency: correlated rise in RSV/COVID could overload capacity and amplify elective-care deferrals, compressing hospital ARPU.

Trade implications: Tactical long exposure to diagnostics (DGX, LH) and selective vaccine/antiviral names (SNY, GSK, MRNA) with 1–3 month horizons, paired with short travel (AAL or IYT) for 4–8 weeks. Options: buy 2–3 month call spreads on DGX/LH to cap cost; buy 1–2 month puts on AAL. Rotate into broader healthcare defensives (HCA, UNH) if hospitalizations remain >30% above prior-season medians for >6 weeks.

Contrarian angles: Consensus underestimates upside for mRNA/platform names (MRNA, PFE) if reformulated shots are fast-tracked — a 6–9 month technology premium could be mispriced. Market may over-penalize travel; past H3N2 severe seasons (2017–18) showed travel demand recovered within 8–12 weeks. Unintended consequence: the CDC’s softened recommendation could compress short-term pediatric vaccine demand but spur state-level mandates and litigation that ultimately benefits large legacy vaccine makers with diversified portfolios.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in Quest Diagnostics (DGX) and/or Laboratory Corp (LH) split 60/40; complement with 2–3 month call spreads (buy 1–2% OTM, sell 10–12% OTM) to express higher testing volumes. Exit or reassess when CDC national influenza hospitalizations decline 30% from current peak or after two consecutive 4-week declines.
• Take a 1–2% long position in Sanofi (SNY) and 0.5–1% in Moderna (MRNA) to play antiviral/vaccine demand and mRNA re-formulation optionality; hold through Q2 2026 and trim if FDA/CDC announces matched-strain vaccine rollout within 3–6 months.
• Short 1–2% in travel-exposed equities (American Airlines AAL or IYT) via 4–8 week puts (buy 1–2 month ATM puts) to capture near-term demand weakness; cover if TSA throughput or hotel occupancy rebounds to >80% of 2019 levels for two consecutive weeks.
• Implement a pair trade: long DGX 2% vs short AAL 2% to capture diagnostic volume gains versus discretionary weakness; use options (long DGX call spread, long AAL put) to limit drawdown and set stop-loss at 6–8% adverse move.
• Increase allocation to hospital/insurer defensives (HCA, UNH) by +1–2% if weekly CDC data shows hospitalizations persist >20% above last season for >6 weeks; trim if hospital utilization normalizes below that threshold.